Applied Therapeutics & Whole Animal Imaging

CCR/KI在使用小鼠研究癌症方面有着长期的记录。在过去的十年中，该中心已经成功地建立了许多小鼠模型，这些模型在促进突变的频谱和它们的表型特征（包括转移状态的进展）方面与人类疾病非常相似。现在，吉隆坡大学的科学家和工程师们都强烈希望使用这些模型来测试潜在的治疗策略，并探索耐药性的机制。此外，这些模型是Kl工程师的关键资源，提供体内系统来测试肿瘤检测和监测设备，药物输送系统和化疗反应。在目前的资助期内，Kl建立了一个新的设施，称为应用治疗学和全动物成像（ATWAI）核心设施，作为支持和鼓励这些转化工作的集中资源。ATWAI岩心的开发经历了两个阶段。最初，核心建立了必要的基础设施，以支持对治疗剂的反应和耐药性的纵向研究，特别是全动物成像模式。该仪器允许中心成员在体内评估肿瘤动力学，包括跟踪肿瘤的发展和转移，并跟踪它们对治疗的反应。接下来，在2008年，一位老鼠模型专家被招募为ATWAI核心的代理经理，目标是最大限度地减少在建立和开展临床前试验中存在的无数障碍。ATWAI经理为中心成员提供广泛和定制的咨询服务、研究者培训和动手实验执行，以实现生物传感器、诊断、疫苗、化疗、基因治疗或药物输送和靶向模式的现场高质量体内试验。因此，ATWAI核心帮助中心成员将小鼠模型用于潜在的治疗，并促进吉隆坡工程师和科学家之间的合作，以允许在适当的体内模型中测试药物传递和肿瘤监测系统。新的科赫研究所大楼计划扩建ATWAI核心，包括增加工作人员和仪器。CCSG的支持对于确保ATWAI核心的成功至关重要，这一目标与NCI推进转化研究的愿望完美契合。

The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contributing mutations and their phenotypic characteristics including progression to the metastatic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detection and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics & Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Initially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and hands-on execution of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targeting modalities. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potential therapies, and spurs collaborations between Kl engineers and scientists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including additional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfectly with the NCI's desire to advance translational research.